REGN logo
REGN
Regeneron Pharmaceuticals

Dupixent And EYLEA Will Seize Expanding Global Markets

Published
08 Apr 25
Updated
15 Aug 25
AnalystHighTarget's Fair Value
US$815.00
28.8% undervalued intrinsic discount
15 Aug
US$580.41
Loading
1Y
-50.8%
7D
3.1%

Author's Valuation

US$815.0

28.8% undervalued intrinsic discount

AnalystHighTarget Fair Value

Narrative
Updates4

Shared on07 May 25
Fair value Decreased 27%

Read more

Shared on30 Apr 25
Fair value Decreased 0.14%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Increased 9.25%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on16 Apr 25
Fair value Increased 9.37%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more